The Research Letter by McCormick and colleagues1 clearly reveals the ripple effect associated with the US Food and Drug Administration (FDA) Unapproved Drug Initiative approval of colchicine (Colcrys). The investigators’ goal was to document the trends in national spending before and after the approval of Colcrys and to secondarily determine the proportion of this spending that was attributable solely to the price increase. Medicaid and Medicare data files through 2017 were used to analyze trends. Among the key findings was that the 2017 combined Medicaid and Medicare claims exceeded $340 million. Medicaid spending for colchicine increased almost 3000%, from $1.1 million in 2008 to $32.2 million in 2017. The investigators confirmed that 58% of the increased spending was due to the price increase alone.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Guglielmo BJ. The Colchicine Debacle Revisited. JAMA Intern Med. 2021;181(2):287–288. doi:10.1001/jamainternmed.2020.5044
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: